NFKB1 and familial pancreatic carcinoma: Shikonin is found to be a potential inhibitor in pancreatic cancer as it mediates PD-L1 degradation which in turn suppresses immune evasion in pancreatic cancer cells via NF-κB/STAT3 and NF-κB/CSN5 signaling pathway (Ruan et al., 2021).